Table 2 Clinical characteristics, effectiveness and safety of the two groups
From: High cumulative doxorubicin dose for advanced soft tissue sarcoma
Characteristics | Standard-dose group (n = 146) | Pre-over-dose group (n = 24) | Over-dose group (n = 24) |
|---|---|---|---|
Accumulative Doxorubicin dose (mg/m2) | 364.04 ± 63.81 | 421.15 ± 47.39 | 714.38 ± 210.09 |
ORR (%) | 15.07% | 100% | 16.67% |
DCR (%) | 58.9% | 100% | 66.67% |
Median-PFS (months) | 6 (95%CI: 5.8–6.5) | 8.15 (95%CI: 5.8–9.5) | 4 (95%CI: 2.0–5.8) |
Incidence of cardiotoxicity (%) | 3.42% | 0% | 4.17% |